Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - INVO Bioscience, Inc. | ex_216577.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 2, 2020
INVO BIOSCIENCE, INC.
(Exact name of registrant as specified in charter)
|
Nevada |
001-39701 |
20-4036208 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer |
|
5582 Broadcast Court Sarasota, Florida (Address of principal executive offices) |
|
34240 (Zip Code) |
|
Registrant’s telephone number, including area code: (978) 878-9505 |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
Common Stock, $0.0001 par value per share |
INVO |
The Nasdaq Stock Market LLC |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☐. |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 1.01. Entry into a Material Definitive Agreement.
On December 2, 2020, we entered into a Distribution Agreement with Tasnim Behboud Arman (“Distributor”) to distribute the INVOcell system to the Islamic Republic of Iran under which Distributor was appointed as the exclusive distributor in the Islamic Republic of Iran. The agreement is for an initial term of one year and can be renewed upon the mutual agreement of the parties. We also granted Distributor a non-exclusive right to the INVO trademarks in Iran in connection with the sale of products in Iran.
The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
10.1 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
INVO BIOSCIENCE, INC. |
||
|
|
|
|
|
|
|
By: |
/s/ Steven Shum |
|
|
|
Name: |
Steven Shum |
|
|
|
Title: |
Chief Executive Officer |
|
|
|
|
|
|
|
Dated December 7, 2020 |
|
|
|